Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600. Please note that this is an emergency number and should only be used in the event of a potentially serious problem with a centrally authorised medicine. Source/Attributions: This news post was originally posted at […]
The condition affects around 270,935 people in England and 16,090 people in Wales The National Institute for Health and Care Excellence (NICE) has published final guidance announcing a five-year roll-out of a wearable technology for patients living with type 1 diabetes. The new hybrid closed loop systems have proven to be more […]
Work programme and budget for 2024 The Board adopted EMA’s work programme for 2024, acknowledging that the Agency will continue to deliver on all its strategic priorities. EMA and the Heads of Medicines Agencies (HMA) plan to review and update the European Medicines Agencies Network Strategy looking ahead to 2028, considering the implementation of EMA’s […]
New data highlights the inequalities in emergency hospital rates and vaccinations The UK Health Security Agency (UKHSA) has highly encouraged eligible individuals from ethnic minority groups and deprived areas to book their influenza and COVID-19 vaccines. A new UKHSA report has highlighted the inequalities in emergency hospital admission rates and the urgent […]
European countries have substantially reduced sales of veterinary antibiotics, which translates into a lower risk of bacteria becoming resistant in people and animals. Overall sales of veterinary antibiotics decreased by 53% between 2011 and 2022, reaching the lowest level ever reported, according to data from 25 countries. This is one of the key findings of […]
The centre will help discover new treatments to prevent, halt and cure the condition The British Heart Foundation (BHF) and the UK Dementia Research Institute (UKDRI) have announced plans to establish the first research centre for vascular dementia research in the UK. The new centre will help discover new treatments to prevent, […]
EMA is advising marketing authorisation holders to submit type IA and type IAIN variations for 2023 no later than Thursday, 30 November 2023. This will enable EMA to acknowledge the validity of the submissions before the Agency’s closure between 25 December 2023 and 3 January 2024 and within the 30-day timeframe set out in Article […]
Over 600 commercial studies have been reviewed in the past 12 months The National Institute for Health and Care Research (NIHR) has revealed that the National Contract Value Review (NCVR) has reduced NHS set-up times for commercial studies. The NCVR has completed over 600 commercial study reviews within the last 12 months. […]
EMA’s human medicines committee (CHMP) has recommended a conditional marketing authorisation in the European Union (EU) for Elrexfio (elranatamab) as a monotherapy (used on its own) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies and whose cancer has worsened since they received their […]
The study will offer new insights into the immune system’s response to iGAS Spencer Dayman Meningitis Research has announced that scientists at the University of Bristol have begun a research project to aid in the development of a vaccine against invasive group A streptococcus (iGAS). The study will offer new and unique […]
